This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
- AID,
- autoimmune diseases
- APS,
- antiphospholipid antibody syndrome
- aPLs,
- antiphospholipid antibodies
- aCLs,
- anticardiolipin antibodies
- CAPS,
- catastrophic antiphospholipid antibody syndrome
- GP-I,
- anti-β-2 glycoprotein I antibodies
- HLA,
- histocompatibility leukocyte antigen
- Ig,
- immunoglobulin
- LA,
- lupus anticoagulant
- SLE,
- systemic lupus erythematosus
Abstract
Antiphospholipid antibody syndrome (APS) during pregnancy may result in pregnancy morbidity and passive transfer of antibodies to the fetus, resulting in an increased risk of prematurity, intrauterine growth restriction, thrombocytopenia, and developmental delay. Antiphospholipid antibodies may have an impact on neurodevelopment during fetal life. Although rare, persistence of these antibodies in the neonate may lead to thromboembolism, particularly if there is a concurrent infection and/or inherited thrombophilic disorders. Affected pregnant women need to be identified early during gestation so that they can have close monitoring of the placental circulation, fetal growth and development, and testing of serum antiphospholipid antibody levels. Neonates born to mothers with antiphospholipid antibody syndrome should have close neurodevelopment follow-up.
- Copyright © 2014 by the American Academy of Pediatrics
Individual Login
Institutional Login
You may be able to gain access using your login credentials for your institution. Contact your librarian or administrator if you do not have a username and password.